Author:
Ogunbusuyi Bolu E.,Oyegue Kelvin O.,Fasoiro Oyindamola,Adeyanju Kolawole,Akpor Oghenerobor B.
Abstract
Background:
Type 2 diabetes mellitus (T2DM) remains one of the non-communicable metabolic disorders associated with serious thrombotic outcomes and risk of cardiovascular disease, which can be fatal.
Aim:
This study was therefore aimed at comparing the levels of haemostatic and haematological parameters of T2DM and non-diabetic subjects. The study also determines the relationship between haemostatic parameters with haematological parameters among the T2DM subjects.
Methods:
Total of 150 participants, comprising “75” of those with diabetes and those without diabetes, were recruited for the study. Blood samples were collected for the analysis of full blood count, Factor V, VII, and tissue plasminogen activator inhibitor-1 (TPA I-1). Test of significance of means was carried out using the One-Way Analysis of variance test, while relationships were tested using Pearson correlation and logistic regression.
Results:
The results revealed significantly higher levels of Factor V, VII, and TPA I-1 among participants with diabetes when compared with those without diabetes. However, significantly lower levels of red cell parameters and red cell indices were observed in the participants with diabetes. In addition, with the exception of lymphocyte and eosinophil levels, all other white blood cells(WBC), platelets, and differential leukocyte parameters were significantly higher in the subjects with diabetes. Moreover, there was a significant positive correlation between Factors V and VII, TPA I – 1 and Factor VII, TPA I-1 and platelets, Factor VII and Haematocrit (HCT) levels in diabetic subjects.
Conclusion:
Conclusively, the correlation between pro-coagulant and hypofibrinolytic factors may be accountable for the hypercoagulability and thrombotic events which characterize T2DM, thereby providing an insight into factor-specific management of the disease with haematological parameters assisting routinely predict factor levels thereafter increasing the ease of prognosis of T2DM.
Publisher
Bentham Science Publishers Ltd.
Reference42 articles.
1. World Health Organisation Nigeria..
Stakeholders call for increased access to diabetes education
2022.
Available from:https://www.afro.who.int/countries/nigeria/news/stakeholders-call-increased-access-diabetes-education#:~:text=Abuja%2C%2015%20November%2C%202022%20%2D,and%20management%20of%20the%20disease.
2. De Rosa S, Arcidiacono B, Chiefari E, Brunetti A, Indolfi C, Foti DP.
Type 2 diabetes mellitus and cardiovascular disease: Genetic and epigenetic links.
Front Endocrinol
2018;
9
: 2.
3. Tripodi A, Branchi A, Chantarangkul V, et al.
Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay.
J Thromb Thrombolysis
2011;
31
(2)
: 165-72.
4. Nieuwdorp M, Stroes ESG, Meijers JCM, Büller H.
Hypercoagulability in the metabolic syndrome.
Curr Opin Pharmacol
2005;
5
(2)
: 155-9.
5. Li X, Weber NC, Cohn DM, et al.
Effects of hyperglycemia and diabetes mellitus on coagulation and hemostasis.
J Clin Med
2021;
10
(11)
: 2419.